10-Q quarterly report · filed Nov 6, 2026

Anika Therapeutics, Inc. (ANIK) Q3 2026 10-Q Quarterly Report

Short answer

Anika Therapeutics, Inc. (ANIK) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $31M (up 10.0% year over year) with net income of −$311,000.

Q3 2026 key financials · XBRL

Revenue
$31M
+10.0% YoY · −6.2% QoQ
Net income
−$311,000
+86.6% YoY · −109.4% QoQ
Operating margin
-2.3%
Gross margin
61.6%
EPS (diluted)
−$0.02
+87.5% YoY · −108.3% QoQ

Source: XBRL data from the Anika Therapeutics, Inc. (ANIK) Q3 2026 10-Q on SEC EDGAR. USD.

Anika Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $30.6M, up 10% YoY from $27.8M, driven by Commercial Channel growth
  • Gross margin 62% vs 56% YoY, with net loss $0.3M vs $3.2M
  • Best segment Commercial Channel revenue $14.0M, up 17%; Integrity sales supported regenerative growth
  • Cash $45.0M vs $57.5M at December 31, 2025; operating cash flow $2.8M vs $6.6M
  • Hyalofast PMA not approvable; Cingal NDA submission targeted by December 31, 2027

Risk Factors

  • No material changes to 2025 Form 10-K risk factors
  • Carried-forward business risk: disclosed risks could materially affect future results
  • Carried-forward uncertainty risk: unknown or currently immaterial risks could materially harm operations

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Anika Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.